Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2013-12-16 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2013-12-16 English
4 Filing
Director's Dealing
2013-12-13 English
4 Filing
Director's Dealing
2013-12-09 English
SC 13G/A Filing
Major Shareholding Notification
2013-12-06 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions that the filing includes a press release with updated financial guidance for the fourth quarter and full year 2013. The document is only 3007 characters long, which is relatively short and primarily serves to announce the press release rather than provide detailed financial statements or analysis. There is no indication of full financial results or comprehensive report content. According to the rules, short filings that announce or attach reports or press releases without containing the full report themselves should be classified as Regulatory Filings (RNS). Therefore, this document is best classified as a Regulatory Filing (RNS) with high confidence.
2013-12-04 English
4 Filing
Director's Dealing
2013-11-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.